- Home
- OPRX vs FATE Comparison
OPRX vs FATE Comparison
Compare OPRX & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OPRX | FATE |
|---|---|---|
| Founded | 2006 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 117.1M | 125.6M |
| IPO Year | 2008 | 2013 |
Fundamental Metrics
Financial Performance| Metric | OPRX | FATE |
|---|---|---|
| Price | $6.38 | $2.43 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 6 |
| Target Price | ★ $16.67 | $4.10 |
| AVG Volume (30 Days) | 301.7K | ★ 3.4M |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 124.55 | 29.88 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $109,429,000.00 | $6,646,000.00 |
| Revenue This Year | $3.88 | N/A |
| Revenue Next Year | $8.34 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 18.78 | N/A |
| 52 Week Low | $4.54 | $0.91 |
| 52 Week High | $22.25 | $3.23 |
Technical Indicators
Market Signals| Indicator | OPRX | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 56.91 | 44.46 |
| Support Level | $6.03 | $1.01 |
| Resistance Level | $6.93 | $3.22 |
| Average True Range (ATR) | 0.24 | 0.21 |
| MACD | -0.04 | -0.09 |
| Stochastic Oscillator | 48.47 | 6.55 |
Price Performance
Historical ComparisonAbout OPRX OptimizeRx Corporation
OptimizeRx Corp is engaged in the healthcare market in the United States. is a digital healthcare technology company that connects over two million HCPs and millions of their patients through an intelligent technology platform embedded within a proprietary omnichannel network. OptimizeRx helps life sciences organizations engage and support their customers through its combined HCP and DTC marketing strategies.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.